Kyntra Bio Inc

KYNB

Healthcare Biotechnology

Kyntra Bio Inc’s revenue for fiscal 2025 (year ended December 2025) was $6.4 million, down 78.3% from fiscal 2024.

Revenue
n/m
EPS
n/m
Free cash flow
n/m

Quarter to June 2026, against a year earlier

3.44 0.15 −4.18%
Market cap
$14.5M
P/E
0.1×
Fwd P/E FY26e
n/m
Dividend yield
—
F-score
5/9
ROIC
0.00%
Net debt / EBITDA
2.0×
Payout ratio
—

Ratios over time Q3 FY25 to Q2 FY26

Returns on capital

ROIC was 0.0% in Q2 FY26, the highest of these four quarters.

ROEROIC
Q3 FY25Q4 FY25Q1 FY26Q2 FY26
ROE−189.9%−165.2%−144.0%−157.8%
ROIC0.0%0.0%0.0%0.0%

Debt

Net debt is 5.17× a year’s EBITDA. Debt is 0.00× equity.

Debt / equityNet debt / EBITDA
Q3 FY25Q4 FY25Q1 FY26Q2 FY26
Debt / equity0.0×0.0×0.0×0.0×
Net debt / EBITDA22.6×6.6×6.2×5.2×

Cash cycle, in days

Customers pay in 27 days, inventory is held 285 days and suppliers are paid in 633. Suppliers fund 321 days of working capital.

Cash cycleDays to pay suppliersDays to be paid
Q3 FY25Q4 FY25Q1 FY26Q2 FY26
Cash cycle8611106−321
Days to pay suppliers−3342458422633
Days to be paid51224727

Per share, from Q3 FY25

Since Q3 FY25, per share: revenue has fallen 44.4%.

Revenue
Q3 FY25Q4 FY25Q1 FY26Q2 FY26
Revenue1.0×0.8×0.9×0.6×
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
0.17 0.17 0.19 0.23

+8 more quarters

P/S ratio
6.62 3.69 5.51 5.97
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(7.66) (1.98) (1.94) (26.82)
P/B ratio
0.00 0.00 0.00 0.00
Price to Tangible BV
0.00 0.00 0.00 0.00
EV/Sales
18.71 11.74 14.55 9.49
EV/EBITDA
0.00 0.00 0.00 0.00
EV/Operating CF
(2.27) (4.09) (19.62) (4.65)
EV/FCF
(2.27) (4.08) (19.47) (4.66)
Quick Ratio
2.54 3.28 3.05 3.28
Current Ratio
2.69 3.61 3.39 3.71
Net Debt/EBITDA
5.17 6.23 6.55 22.61
Debt/Assets
0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00
Asset Turnover
0.03 0.05 0.04 0.04
Operating CF/Net income
(0.33) 0.91 1.29 (0.01)
Capex/Depreciation
0.00 0.00 0.00 (0.05)
Interest Coverage
(7.42) (5.69) (5.61) (2.60)
Research and Development Expense of Revenue
(462.75%) 202.41% 569.15% 112.36%
Selling, General and Administrative Expense of Revenue
(628.63%) 156.82% 567.82% 492.10%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
(66.76%) 30.79% 93.11% 61.52%
Graham Net Nets
(1.11) (1.42) (1.06) (0.15)
Graham Number
0.00 0.00 0.00 0.00
Earnings Yield
600.00% 596.76% 517.88% 436.57%
Free Cash Flow Yield
(124.63%) (78.06%) (13.56%) (34.08%)
Revenue per Share
(0.36) 0.92 0.32 0.27
Operating CF per Share
(0.99) (3.43) (4.53) (0.46)
Capex per Share
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(0.99) (3.43) (4.53) (0.46)
Cash per Share
22.56 21.56 22.01 29.17
Shareholders Equity per Share
(7.32) (7.60) (4.21) (0.99)
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
(7.32) (7.60) (4.21) (0.99)
Free Cash Flow
(3.99) (13.89) (18.33) (1.86)
Working Capital
60.79 73.24 69.83 97.45
Capital Expenditures
— — 0.00 (0.01)
Net Current Asset Value
(33.88) (39.04) (37.53) (7.59)
EV/EBIT
0.00 0.00 0.00 0.00
Capex to Sales
0.00 0.00 0.00 0.01
Price to Operating Income
0.00 0.00 0.00 0.00
Other line items
Average Receivables
0.24 2.59 0.35 14.58
Average Payables
8.99 6.19 4.40 7.17
Average Inventory
3.62 3.27 3.45 13.90
Average Assets
139.57 137.42 167.06 200.72
Average Common Equity
(116.07) (113.59) (111.06) (113.59)

Fold the line items

Columns are period end dates · fundamentals updated 25 Oct 2026